Endeavor BioMedicines reveals encouraging results for ENV-101 in Phase 2a idiopathic pulmonary fibrosis trial
Endeavor BioMedicines, a clinical-stage biotechnology company, has announced encouraging results from their completed Phase 2a clinical trial of ENV-101, showing improved lung function and a reversal in key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Presented at the American Thoracic Society 2024 International Conference, these findings mark a potential breakthrough in […]